Focused on

Growth and Innovation

"Patients are at the heart of what we do"

Investor presentation

November 24, 2022

Table of contents

  • Executive summary
  • Portfolio
    • Antifungal
      • Cresemba® (isavuconazole)
    • Antibiotic
      • Zevtera® (ceftobiprole)
  • Financials & Outlook
  • Appendix

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

2

Executive summary

Experienced leadership team

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

4

At a glance

  • Focus on the treatment of serious bacterial and fungal infections
  • Recognized ability to establish and manage partnerships in both the development and commercial phase
  • Cresemba® and Zevtera® - two revenue generating hospital anti-infective brands
  • Commercial products complemented by programs which are in an earlier stage of development
  • On track to achieve sustainable profitability in 2023
  • Listed on SIX Swiss Stock Exchange, SIX: BSLN
  • Located in the Basel area life sciences hub, Switzerland

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Basilea Pharmaceutica AG published this content on 24 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2022 16:53:06 UTC.